Stoke Therapeutics Financials
This page shows Stoke Therapeutics (STOK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Stoke Therapeutics has an operating margin of -11.2%, meaning the company retains $-11 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -277.3% the prior year.
Stoke Therapeutics's revenue surged 404.5% year-over-year to $184.4M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Stoke Therapeutics carries a low D/E ratio of 0.19, meaning only $0.19 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.28, Stoke Therapeutics holds $5.28 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Stoke Therapeutics converts 24.3% of revenue into free cash flow ($44.9M). This strong cash generation earns a score of 86/100.
Stoke Therapeutics generates a -1.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 7/100. This is up from -38.9% the prior year.
Stoke Therapeutics passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Stoke Therapeutics generates $-6.62 in operating cash flow ($45.6M OCF vs -$6.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Stoke Therapeutics earns $-2287.8 in operating income for every $1 of interest expense (-$20.6M vs $9K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Stoke Therapeutics generated $184.4M in revenue in fiscal year 2025. This represents an increase of 404.5% from the prior year.
Stoke Therapeutics's EBITDA was -$18.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 81.0% from the prior year.
Stoke Therapeutics reported -$6.9M in net income in fiscal year 2025. This represents an increase of 92.3% from the prior year.
Stoke Therapeutics earned $-0.12 per diluted share (EPS) in fiscal year 2025. This represents an increase of 92.7% from the prior year.
Cash & Balance Sheet
Stoke Therapeutics generated $44.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 151.6% from the prior year.
Stoke Therapeutics held $84.2M in cash against $0 in long-term debt as of fiscal year 2025.
Stoke Therapeutics had 59M shares outstanding in fiscal year 2025. This represents an increase of 9.0% from the prior year.
Margins & Returns
Stoke Therapeutics's operating margin was -11.2% in fiscal year 2025, reflecting core business profitability. This is up 266.1 percentage points from the prior year.
Stoke Therapeutics's net profit margin was -3.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 239.7 percentage points from the prior year.
Stoke Therapeutics's ROE was -1.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 36.9 percentage points from the prior year.
Capital Allocation
Stoke Therapeutics invested $137.9M in research and development in fiscal year 2025. This represents an increase of 54.7% from the prior year.
Stoke Therapeutics invested $670K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 230.0% from the prior year.
STOK Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M-86.8% | $10.6M-23.1% | $13.8M-91.3% | $158.6M+601.2% | $22.6M+362.1% | $4.9M+1.3% | $4.8M+14.6% | $4.2M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $41.7M+10.6% | $37.7M+45.8% | $25.9M-20.9% | $32.7M+39.5% | $23.4M+5.5% | $22.2M+5.1% | $21.1M-5.5% | $22.4M |
| SG&A Expenses | $21.1M+31.9% | $16.0M+5.0% | $15.3M+4.2% | $14.7M+14.1% | $12.8M+1.2% | $12.7M-2.6% | $13.0M+27.6% | $10.2M |
| Operating Income | -$61.4M-42.6% | -$43.1M-57.8% | -$27.3M-124.5% | $111.2M+914.6% | -$13.7M+54.5% | -$30.0M-2.3% | -$29.3M-3.4% | -$28.4M |
| Interest Expense | $2K-33.3% | $3K0.0% | $3K+200.0% | $1K+200.0% | -$1K | $0-100.0% | $5K-77.3% | $22K |
| Income Tax | $0+100.0% | -$1.3M | $0-100.0% | $1.3M | N/A | $0 | $0 | $0 |
| Net Income | -$57.9M-51.1% | -$38.3M-63.3% | -$23.5M-120.8% | $112.9M+1176.9% | -$10.5M+60.3% | -$26.4M-2.9% | -$25.7M+2.6% | -$26.4M |
| EPS (Diluted) | N/A | $-0.65-62.5% | $-0.40-121.1% | $1.90 | N/A | $-0.47-2.2% | $-0.46+19.3% | $-0.57 |
STOK Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $418.4M+16.1% | $360.3M-6.3% | $384.5M-5.5% | $406.9M+49.8% | $271.6M-7.4% | $293.3M-4.7% | $307.8M+50.0% | $205.2M |
| Current Assets | $305.7M+12.2% | $272.4M+0.9% | $270.0M-28.1% | $375.7M+61.4% | $232.8M-8.2% | $253.6M-14.6% | $297.0M+53.7% | $193.3M |
| Cash & Equivalents | $84.2M+1.0% | $83.4M-17.8% | $101.5M-63.1% | $274.8M+114.7% | $128.0M-14.7% | $150.0M-22.5% | $193.5M+8.3% | $178.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $5.9M-35.8% | $9.2M | N/A | N/A | $1.7M | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $66.0M+26.5% | $52.2M+5.2% | $49.6M-12.8% | $56.8M+33.6% | $42.5M-30.5% | $61.2M-5.9% | $65.0M+0.3% | $64.8M |
| Current Liabilities | $57.9M+38.7% | $41.7M+7.9% | $38.7M-13.4% | $44.7M+11.6% | $40.1M-19.7% | $49.9M+12.1% | $44.5M+25.0% | $35.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $352.5M+14.4% | $308.1M-8.0% | $334.9M-4.3% | $350.1M+52.9% | $229.0M-1.3% | $232.1M-4.4% | $242.7M+72.9% | $140.3M |
| Retained Earnings | -$497.7M-13.2% | -$439.8M-9.6% | -$401.4M-6.2% | -$378.0M+23.0% | -$490.8M-2.2% | -$480.3M-5.8% | -$453.9M-6.0% | -$428.2M |
STOK Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$30.5M-0.3% | -$30.4M-19.4% | -$25.4M-119.3% | $131.8M+668.4% | -$23.2M-7.3% | -$21.6M-23.7% | -$17.5M+28.9% | -$24.6M |
| Capital Expenditures | $232K+75.8% | $132K-14.3% | $154K+1.3% | $152K+261.9% | $42K-59.2% | $103K+123.9% | $46K+283.3% | $12K |
| Free Cash Flow | -$30.7M-0.6% | -$30.5M-19.2% | -$25.6M-119.4% | $131.7M+666.7% | -$23.2M-7.0% | -$21.7M-23.9% | -$17.5M+28.7% | -$24.6M |
| Investing Cash Flow | -$61.1M-771.4% | $9.1M+106.1% | -$148.5M-1189.2% | $13.6M+1564.5% | $819K+102.7% | -$30.0M+66.0% | -$88.3M-983.8% | $10.0M |
| Financing Cash Flow | $92.3M+2859.6% | $3.1M+463.2% | $554K-59.7% | $1.4M+141.9% | $568K-93.0% | $8.2M-93.2% | $120.7M+6926.8% | $1.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
STOK Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -4382.2%-3976.9pp | -405.3%-207.7pp | -197.6%-267.7pp | 70.2%+130.5pp | -60.4%+552.7pp | -613.1%-5.7pp | -607.4%+65.6pp | -673.0% |
| Net Margin | -4132.2%-3771.6pp | -360.7%-190.7pp | -170.0%-241.2pp | 71.2%+117.5pp | -46.4%+493.7pp | -540.0%-8.2pp | -531.9%+93.7pp | -625.6% |
| Return on Equity | -16.4%-4.0pp | -12.4%-5.4pp | -7.0%-39.3pp | 32.2%+36.8pp | -4.6%+6.8pp | -11.4%-0.8pp | -10.6%+8.2pp | -18.8% |
| Return on Assets | -13.9%-3.2pp | -10.6%-4.5pp | -6.1%-33.8pp | 27.7%+31.6pp | -3.9%+5.1pp | -9.0%-0.7pp | -8.3%+4.5pp | -12.8% |
| Current Ratio | 5.28-1.2 | 6.53-0.5 | 6.98-1.4 | 8.41+2.6 | 5.81+0.7 | 5.09-1.6 | 6.67+1.2 | 5.43 |
| Debt-to-Equity | 0.19+0.0 | 0.17+0.0 | 0.15-0.0 | 0.16-0.0 | 0.19-0.1 | 0.260.0 | 0.27-0.2 | 0.46 |
| FCF Margin | -2188.7%-1901.9pp | -286.9%-101.7pp | -185.1%-268.1pp | 83.0%+185.8pp | -102.8%+341.0pp | -443.8%-81.1pp | -362.7%+220.2pp | -583.0% |
Similar Companies
Frequently Asked Questions
What is Stoke Therapeutics's annual revenue?
Stoke Therapeutics (STOK) reported $184.4M in total revenue for fiscal year 2025. This represents a 404.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Stoke Therapeutics's revenue growing?
Stoke Therapeutics (STOK) revenue grew by 404.5% year-over-year, from $36.6M to $184.4M in fiscal year 2025.
Is Stoke Therapeutics profitable?
No, Stoke Therapeutics (STOK) reported a net income of -$6.9M in fiscal year 2025, with a net profit margin of -3.7%.
What is Stoke Therapeutics's EBITDA?
Stoke Therapeutics (STOK) had EBITDA of -$18.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Stoke Therapeutics's operating margin?
Stoke Therapeutics (STOK) had an operating margin of -11.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Stoke Therapeutics's net profit margin?
Stoke Therapeutics (STOK) had a net profit margin of -3.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Stoke Therapeutics's return on equity (ROE)?
Stoke Therapeutics (STOK) has a return on equity of -1.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Stoke Therapeutics's free cash flow?
Stoke Therapeutics (STOK) generated $44.9M in free cash flow during fiscal year 2025. This represents a 151.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Stoke Therapeutics's operating cash flow?
Stoke Therapeutics (STOK) generated $45.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Stoke Therapeutics's total assets?
Stoke Therapeutics (STOK) had $418.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Stoke Therapeutics's capital expenditures?
Stoke Therapeutics (STOK) invested $670K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Stoke Therapeutics spend on research and development?
Stoke Therapeutics (STOK) invested $137.9M in research and development during fiscal year 2025.
What is Stoke Therapeutics's current ratio?
Stoke Therapeutics (STOK) had a current ratio of 5.28 as of fiscal year 2025, which is generally considered healthy.
What is Stoke Therapeutics's debt-to-equity ratio?
Stoke Therapeutics (STOK) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Stoke Therapeutics's return on assets (ROA)?
Stoke Therapeutics (STOK) had a return on assets of -1.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Stoke Therapeutics's Piotroski F-Score?
Stoke Therapeutics (STOK) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Stoke Therapeutics's earnings high quality?
Stoke Therapeutics (STOK) has an earnings quality ratio of -6.62x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Stoke Therapeutics cover its interest payments?
Stoke Therapeutics (STOK) has an interest coverage ratio of -2287.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Stoke Therapeutics?
Stoke Therapeutics (STOK) scores 65 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.